source
- BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF from Chinese biotechBeOne Medicines, formerly known as BeiGene, announced a licensing agreement with a Chinese biotechnology firm to obtain rights to an experimental trispecific antibody. The antibody is engineered t…
- Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseasesCoultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…